Receptos, a biotech with a Phase 3 drug candidate for relapsing multiple sclerosis, filed on Thursday with the SEC to raise up to $86 million in an initial public offering. The San Diego, CA-based company, which was founded in 2008 and has yet to generate any revenue from drug sales, plans to list on the NASDAQ under the symbol RCPT.
